Around 47,700 men are diagnosed with prostate cancer in the UK each year, making it the most common cancer in men in the UK. It develops in the prostate, a walnut-sized gland found at the base of the bladder.
One of the biggest meetings of the world’s cancer specialists took place this weekend. Usually located in Chicago, researchers and clinicians around the world met virtually this year to present the latest in cancer research at the American Society of Clinical Oncology (ASCO) annual meeting. Here’s a flavour of the some of the top research presented.
Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.
A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.
A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.
A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.
A prostate cancer drug won’t be offered on the NHS any earlier in the treatment plans of patients living with the disease in England.